{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:09:17Z","timestamp":1777900157596,"version":"3.51.4"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007002","name":"DOE | Small Business Innovative Research and Small Business Technology Transfer (Small Business Innovation Research (SBIR) and Small Business Technology Transfer","doi-asserted-by":"publisher","award":["CA275560-01"],"award-info":[{"award-number":["CA275560-01"]}],"id":[{"id":"10.13039\/100007002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007002","name":"DOE | Small Business Innovative Research and Small Business Technology Transfer (Small Business Innovation Research (SBIR) and Small Business Technology Transfer","doi-asserted-by":"publisher","award":["CA275560-01"],"award-info":[{"award-number":["CA275560-01"]}],"id":[{"id":"10.13039\/100007002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007002","name":"DOE | Small Business Innovative Research and Small Business Technology Transfer (Small Business Innovation Research (SBIR) and Small Business Technology Transfer","doi-asserted-by":"publisher","award":["CA275560-01"],"award-info":[{"award-number":["CA275560-01"]}],"id":[{"id":"10.13039\/100007002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA15083"],"award-info":[{"award-number":["P30CA15083"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA15083"],"award-info":[{"award-number":["P30CA15083"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-09155-9","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T11:44:20Z","timestamp":1768477460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Radiotherapy plus neoadjuvant and concomitant IL-13R\u03b12-directed immunotoxin therapy for diffuse intrinsic pontine glioma"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0855-3297","authenticated-orcid":false,"given":"Julian S.","family":"Rechberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2607-909X","authenticated-orcid":false,"given":"Wouter J. F.","family":"Vanbilloen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo F.","family":"Nonnenbroich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jizhi","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randy S.","family":"Schrecengost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8842-5975","authenticated-orcid":false,"given":"Rachael A.","family":"Vaubel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0702-1459","authenticated-orcid":false,"given":"David J.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"9155_CR1","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noac161","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol. 24, iii1\u2013iii38 (2022).","journal-title":"Neuro Oncol."},{"key":"9155_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"9155_CR3","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1093\/jnci\/djad115","volume":"115","author":"DA Siegel","year":"2023","unstructured":"Siegel, D. A. et al. Counts, incidence rates, and trends of pediatric cancer in the United States, 2003-2019. J. Natl. Cancer Inst. 115, 1337\u20131354 (2023).","journal-title":"J. Natl. Cancer Inst."},{"key":"9155_CR4","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","volume":"23","author":"QT Ostrom","year":"2021","unstructured":"Ostrom, Q. T., Cioffi, G., Waite, K., Kruchko, C. & Barnholtz-Sloan, J. S. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol. 23, iii1\u2013iii105 (2021).","journal-title":"Neuro Oncol."},{"key":"9155_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1470-2045(06)70615-5","volume":"7","author":"D Hargrave","year":"2006","unstructured":"Hargrave, D., Bartels, U. & Bouffet, E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 7, 241\u2013248 (2006).","journal-title":"Lancet Oncol."},{"key":"9155_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3389\/fonc.2012.00205","volume":"2","author":"KE Warren","year":"2012","unstructured":"Warren, K. E. Diffuse intrinsic pontine glioma: poised for progress. Front. Oncol. 2, 205 (2012).","journal-title":"Front. Oncol."},{"key":"9155_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/neuonc\/noy070","volume":"20","author":"N Gupta","year":"2018","unstructured":"Gupta, N. et al. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 20, 1547\u20131555 (2018).","journal-title":"Neuro Oncol."},{"key":"9155_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3171\/2023.5.PEDS22557","volume":"32","author":"JS Rechberger","year":"2023","unstructured":"Rechberger, J. S. et al. Feasibility of probe washing after stereotactic needle biopsy as a novel technique for developing cell lines and xenografts of H3 K27-altered diffuse midline gliomas. J. Neurosurg. Pediatr. 32, 413\u2013420 (2023).","journal-title":"J. Neurosurg. Pediatr."},{"key":"9155_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3171\/2023.7.PEDS22462","volume":"32","author":"M Dalmage","year":"2023","unstructured":"Dalmage, M. et al. Survival and neurological outcomes after stereotactic biopsy of diffuse intrinsic pontine glioma: a systematic review. J. Neurosurg. Pediatr. 32, 665\u2013672 (2023).","journal-title":"J. Neurosurg. Pediatr."},{"key":"9155_CR10","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/neuonc\/nox107","volume":"19","author":"T Cooney","year":"2017","unstructured":"Cooney, T. et al. Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. Neuro Oncol. 19, 1279\u20131280 (2017).","journal-title":"Neuro Oncol."},{"key":"9155_CR11","doi-asserted-by":"publisher","unstructured":"Saratsis, A. M., Knowles, T., Petrovic, A. & Nazarian, J. H3K27M Mutant Glioma: disease definition and biological underpinnings. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noad164 (2023).","DOI":"10.1093\/neuonc\/noad164"},{"key":"9155_CR12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00381-019-04463-y","volume":"36","author":"M Giagnacovo","year":"2020","unstructured":"Giagnacovo, M. et al. Retrospective analysis on the consistency of MRI features with histological and molecular markers in diffuse intrinsic pontine glioma (DIPG). Childs Nerv. Syst. 36, 697\u2013704 (2020).","journal-title":"Childs Nerv. Syst."},{"key":"9155_CR13","first-page":"vdab042","volume":"3","author":"LT Tam","year":"2021","unstructured":"Tam, L. T. et al. MRI-based radiomics for prognosis of pediatric diffuse intrinsic pontine glioma: an international study. Neurooncol. Adv. 3, vdab042 (2021).","journal-title":"Neurooncol. Adv."},{"key":"9155_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00381-019-04363-1","volume":"36","author":"JS Rechberger","year":"2020","unstructured":"Rechberger, J. S., Lu, V. M., Zhang, L., Power, E. A. & Daniels, D. J. Clinical trials for diffuse intrinsic pontine glioma: the current state of affairs. Childs Nerv. Syst. 36, 39\u201346 (2020).","journal-title":"Childs Nerv. Syst."},{"key":"9155_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000529099","volume":"58","author":"C Dalle Ore","year":"2023","unstructured":"Dalle Ore, C., Coleman, C., Gupta, N. & Mueller, S. Advances and clinical trials update in the treatment of diffuse intrinsic pontine gliomas. Pediatr. Neurosurg. 58, 259\u2013266 (2023).","journal-title":"Pediatr. Neurosurg."},{"key":"9155_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14791\/btrt.2022.0041","volume":"11","author":"HJ Kim","year":"2023","unstructured":"Kim, H. J. & Suh, C. O. Radiotherapy for diffuse intrinsic pontine glioma: insufficient but indispensable. Brain Tumor Res. Treat. 11, 79\u201385 (2023).","journal-title":"Brain Tumor Res. Treat."},{"key":"9155_CR17","doi-asserted-by":"publisher","first-page":"e0193565","DOI":"10.1371\/journal.pone.0193565","volume":"13","author":"NE Berlow","year":"2018","unstructured":"Berlow, N. E. et al. IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma. PLoS ONE 13, e0193565 (2018).","journal-title":"PLoS ONE"},{"key":"9155_CR18","first-page":"1168","volume":"60","author":"BH Joshi","year":"2000","unstructured":"Joshi, B. H., Plautz, G. E. & Puri, R. K. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res. 60, 1168\u20131172 (2000).","journal-title":"Cancer Res."},{"key":"9155_CR19","first-page":"1103","volume":"62","author":"SO Rahaman","year":"2002","unstructured":"Rahaman, S. O. et al. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res. 62, 1103\u20131109 (2002).","journal-title":"Cancer Res."},{"key":"9155_CR20","first-page":"4702","volume":"12","author":"J Zeng","year":"2020","unstructured":"Zeng, J. et al. IL13RA2 is overexpressed in malignant gliomas and related to clinical outcome of patients. Am. J. Transl. Res. 12, 4702\u20134714 (2020).","journal-title":"Am. J. Transl. Res."},{"key":"9155_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.str.2010.01.003","volume":"18","author":"PJ Lupardus","year":"2010","unstructured":"Lupardus, P. J., Birnbaum, M. E. & Garcia, K. C. Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2. Structure 18, 332\u2013342 (2010).","journal-title":"Structure"},{"key":"9155_CR22","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1002\/smll.201400654","volume":"10","author":"Y Cheng","year":"2014","unstructured":"Cheng, Y. et al. Blood-brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging. Small 10, 5137\u20135150 (2014).","journal-title":"Small"},{"key":"9155_CR23","doi-asserted-by":"publisher","first-page":"14701","DOI":"10.1007\/s13277-016-5346-x","volume":"37","author":"M Tu","year":"2016","unstructured":"Tu, M. et al. IL-13 receptor \u03b12 stimulates human glioma cell growth and metastasis through the Src\/PI3K\/Akt\/mTOR signaling pathway. Tumour Biol. 37, 14701\u201314709 (2016).","journal-title":"Tumour Biol."},{"key":"9155_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1746-6","volume":"16","author":"R Bhardwaj","year":"2018","unstructured":"Bhardwaj, R., Suzuki, A., Leland, P., Joshi, B. H. & Puri, R. K. Identification of a novel role of IL-13R\u03b12 in human Glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway. J. Transl. Med. 16, 369 (2018).","journal-title":"J. Transl. Med."},{"key":"9155_CR25","first-page":"985","volume":"5","author":"W Debinski","year":"1999","unstructured":"Debinski, W., Gibo, D. M., Hulet, S. W., Connor, J. R. & Gillespie, G. Y. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin. Cancer Res. 5, 985\u2013990 (1999).","journal-title":"Clin. Cancer Res."},{"key":"9155_CR26","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/cncr.20470","volume":"101","author":"M Kawakami","year":"2004","unstructured":"Kawakami, M., Kawakami, K., Takahashi, S., Abe, M. & Puri, R. K. Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors. Cancer 101, 1036\u20131042 (2004).","journal-title":"Cancer"},{"key":"9155_CR27","doi-asserted-by":"publisher","unstructured":"Li, X. et al. Expression of Interleukin-13 Receptor Alpha 2 in Brainstem Gliomas. Cancers 16, https:\/\/doi.org\/10.3390\/cancers16010228 (2024).","DOI":"10.3390\/cancers16010228"},{"key":"9155_CR28","doi-asserted-by":"publisher","first-page":"16775","DOI":"10.1074\/jbc.270.28.16775","volume":"270","author":"W Debinski","year":"1995","unstructured":"Debinski, W., Obiri, N. I., Pastan, I. & Puri, R. K. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. Biol. Chem. 270, 16775\u201316780 (1995).","journal-title":"J. Biol. Chem."},{"key":"9155_CR29","first-page":"1253","volume":"1","author":"W Debinski","year":"1995","unstructured":"Debinski, W., Obiri, N. I., Powers, S. K., Pastan, I. & Puri, R. K. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin. Cancer Res. 1, 1253\u20131258 (1995).","journal-title":"Clin. Cancer Res."},{"key":"9155_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1023\/B:NEON.0000024219.47447.91","volume":"67","author":"MM Souweidane","year":"2004","unstructured":"Souweidane, M. M., Occhiogrosso, G., Mark, E. B. & Edgar, M. A. Interstitial infusion of IL13-PE38QQR in the rat brain stem. J. Neurooncol. 67, 287\u2013293 (2004).","journal-title":"J. Neurooncol."},{"key":"9155_CR31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40478-021-01184-9","volume":"9","author":"X Lian","year":"2021","unstructured":"Lian, X. et al. Design considerations of an IL13R\u03b12 antibody-drug conjugate for diffuse intrinsic pontine glioma. Acta Neuropathol. Commun. 9, 88 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"9155_CR32","doi-asserted-by":"publisher","unstructured":"Rechberger, J. S. et al. IL-13R\u03b12 status predicts GB-13 (IL13.E13K-PE4E) efficacy in high-grade glioma. Pharmaceutics 14, https:\/\/doi.org\/10.3390\/pharmaceutics14050922 (2022).","DOI":"10.3390\/pharmaceutics14050922"},{"key":"9155_CR33","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","volume":"21","author":"CE Brown","year":"2015","unstructured":"Brown, C. E. et al. Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin. Cancer Res. 21, 4062\u20134072 (2015).","journal-title":"Clin. Cancer Res."},{"key":"9155_CR34","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561\u20132569 (2016).","journal-title":"N. Engl. J. Med."},{"key":"9155_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","volume":"26","author":"CE Brown","year":"2018","unstructured":"Brown, C. E. et al. Optimization of IL13R\u03b12-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma. Mol. Ther. 26, 31\u201344 (2018).","journal-title":"Mol. Ther."},{"key":"9155_CR36","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1227\/01.neu.0000303199.77370.9e","volume":"61","author":"MA Vogelbaum","year":"2007","unstructured":"Vogelbaum, M. A. et al. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 61, 1031\u20131037 (2007). discussion 1037\u20131038.","journal-title":"Neurosurgery"},{"key":"9155_CR37","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/neuonc\/nop054","volume":"12","author":"S Kunwar","year":"2010","unstructured":"Kunwar, S. et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol. 12, 871\u2013881 (2010).","journal-title":"Neuro Oncol."},{"key":"9155_CR38","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3171\/2013.11.PEDS136","volume":"13","author":"P Chittiboina","year":"2014","unstructured":"Chittiboina, P., Heiss, J. D., Warren, K. E. & Lonser, R. R. Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas. J. Neurosurg. Pediatr. 13, 276\u2013282 (2014).","journal-title":"J. Neurosurg. Pediatr."},{"key":"9155_CR39","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3171\/2018.9.PEDS17225","volume":"23","author":"JD Heiss","year":"2018","unstructured":"Heiss, J. D. et al. Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma. J. Neurosurg. Pediatr. 23, 333\u2013342 (2018).","journal-title":"J. Neurosurg. Pediatr."},{"key":"9155_CR40","doi-asserted-by":"crossref","unstructured":"Mrowczynski, O. D. et al. Targeting IL-13R\u03b12 for effective treatment of malignant peripheral nerve sheath tumors in mouse models. J. Neurosurg. 131, 1369\u20131379 (2018)","DOI":"10.3171\/2018.7.JNS18284"},{"key":"9155_CR41","doi-asserted-by":"publisher","first-page":"15953","DOI":"10.1016\/S0021-9258(18)71572-X","volume":"264","author":"Y Jinno","year":"1989","unstructured":"Jinno, Y. et al. Domain II mutants of Pseudomonas exotoxin deficient in translocation. J. Biol. Chem. 264, 15953\u201315959 (1989).","journal-title":"J. Biol. Chem."},{"key":"9155_CR42","doi-asserted-by":"publisher","first-page":"16306","DOI":"10.1016\/S0021-9258(17)46223-5","volume":"265","author":"VK Chaudhary","year":"1990","unstructured":"Chaudhary, V. K., Jinno, Y., Gallo, M. G., FitzGerald, D. & Pastan, I. Mutagenesis of Pseudomonas exotoxin in identification of sequences responsible for the animal toxicity. J. Biol. Chem. 265, 16306\u201316310 (1990).","journal-title":"J. Biol. Chem."},{"key":"9155_CR43","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1182\/blood.V87.10.4333.bloodjournal87104333","volume":"87","author":"RK Puri","year":"1996","unstructured":"Puri, R. K. et al. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 87, 4333\u20134339 (1996).","journal-title":"Blood"},{"key":"9155_CR44","doi-asserted-by":"publisher","first-page":"46669","DOI":"10.1074\/jbc.M206916200","volume":"277","author":"S Armstrong","year":"2002","unstructured":"Armstrong, S., Yates, S. P. & Merrill, A. R. Insight into the catalytic mechanism of Pseudomonas aeruginosa exotoxin A. Studies of toxin interaction with eukaryotic elongation factor-2. J. Biol. Chem. 277, 46669\u201346675 (2002).","journal-title":"J. Biol. Chem."},{"key":"9155_CR45","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1128\/MCB.00813-09","volume":"30","author":"X Du","year":"2010","unstructured":"Du, X., Youle, R. J., FitzGerald, D. J. & Pastan, I. Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1. Mol. Cell. Biol. 30, 3444\u20133452 (2010).","journal-title":"Mol. Cell. Biol."},{"key":"9155_CR46","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1006\/gyno.2000.6040","volume":"80","author":"M Schmidt","year":"2001","unstructured":"Schmidt, M. et al. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. Gynecol. Oncol. 80, 145\u2013155 (2001).","journal-title":"Gynecol. Oncol."},{"key":"9155_CR47","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1158\/1078-0432.CCR-06-0441","volume":"12","author":"R Hassan","year":"2006","unstructured":"Hassan, R. et al. Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts. Clin. Cancer Res. 12, 4983\u20134988 (2006).","journal-title":"Clin. Cancer Res."},{"key":"9155_CR48","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"9155_CR49","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).","journal-title":"Sci. Signal."},{"key":"9155_CR50","doi-asserted-by":"publisher","unstructured":"de Bruijn, I. et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-0816 (2023).","DOI":"10.1158\/0008-5472.Can-23-0816"},{"key":"9155_CR51","doi-asserted-by":"publisher","first-page":"100340","DOI":"10.1016\/j.xgen.2023.100340","volume":"3","author":"JA Shapiro","year":"2023","unstructured":"Shapiro, J. A. et al. OpenPBTA: the open pediatric brain tumor atlas. Cell Genom. 3, 100340 (2023).","journal-title":"Cell Genom."},{"key":"9155_CR52","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 48, W488\u2013w493 (2020).","journal-title":"Nucleic Acids Res."},{"key":"9155_CR53","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng, S. et al. SynergyFinder Plus: toward better interpretation and annotation of drug combination screening datasets. Genom. Proteom. Bioinform. 20, 587\u2013596 (2022).","journal-title":"Genom. Proteom. Bioinform."},{"key":"9155_CR54","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","volume":"26","author":"CI Bliss","year":"1939","unstructured":"Bliss, C. I. The toxicity of poisons applied jointly 1. Ann. Appl. Biol. 26, 585\u2013615 (1939).","journal-title":"Ann. Appl. Biol."},{"key":"9155_CR55","first-page":"285","volume":"3","author":"S Loewe","year":"1953","unstructured":"Loewe, S. The problem of synergism and antagonism of combined drugs. Arzneim. Forsch. 3, 285\u2013290 (1953).","journal-title":"Arzneim. Forsch."},{"key":"9155_CR56","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0031-6997(25)00026-2","volume":"41","author":"MC Berenbaum","year":"1989","unstructured":"Berenbaum, M. C. What is synergy? Pharm. Rev. 41, 93\u2013141 (1989).","journal-title":"Pharm. Rev."},{"key":"9155_CR57","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav, B., Wennerberg, K., Aittokallio, T. & Tang, J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput. Struct. Biotechnol. J. 13, 504\u2013513 (2015).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"9155_CR58","doi-asserted-by":"publisher","first-page":"e92444","DOI":"10.1371\/journal.pone.0092444","volume":"9","author":"C Guzm\u00e1n","year":"2014","unstructured":"Guzm\u00e1n, C., Bagga, M., Kaur, A., Westermarck, J. & Abankwa, D. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS ONE 9, e92444 (2014).","journal-title":"PLoS ONE"},{"key":"9155_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-8-98","volume":"8","author":"CS Djuzenova","year":"2013","unstructured":"Djuzenova, C. S. et al. Radiosensitivity in breast cancer assessed by the histone \u03b3-H2AX and 53BP1 foci. Radiat. Oncol. 8, 98 (2013).","journal-title":"Radiat. Oncol."},{"key":"9155_CR60","doi-asserted-by":"publisher","first-page":"eadj5962","DOI":"10.1126\/scitranslmed.adj5962","volume":"16","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization. Sci. Transl. Med. 16, eadj5962 (2024).","journal-title":"Sci. Transl. Med."},{"key":"9155_CR61","doi-asserted-by":"publisher","unstructured":"Ji, J. et al. Differential distribution of the DNA-PKcs inhibitor peposertib selectively radiosensitizes patient-derived melanoma brain metastasis xenografts. Mol. Cancer Ther. https:\/\/doi.org\/10.1158\/1535-7163.Mct-23-0552 (2024).","DOI":"10.1158\/1535-7163.Mct-23-0552"},{"key":"9155_CR62","first-page":"vdad033","volume":"5","author":"EA Power","year":"2023","unstructured":"Power, E. A. et al. Overcoming translational barriers in H3K27-altered diffuse midline glioma: Increasing the drug-tumor residence time. Neurooncol. Adv. 5, vdad033 (2023).","journal-title":"Neurooncol. Adv."},{"key":"9155_CR63","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ccell.2018.11.015","volume":"35","author":"JD Larson","year":"2019","unstructured":"Larson, J. D. et al. Histone H3.3 K27M accelerates spontaneous brainstem glioma and drives restricted changes in bivalent gene expression. Cancer Cell 35, 140\u2013155.e147 (2019).","journal-title":"Cancer Cell"},{"key":"9155_CR64","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00381-017-3352-y","volume":"33","author":"A Morales La Madrid","year":"2017","unstructured":"Morales La Madrid, A. et al. Second re-irradiation for DIPG progression, re-considering \u201cold strategies\u201d with new approaches. Childs Nerv. Syst. 33, 849\u2013852 (2017).","journal-title":"Childs Nerv. Syst."},{"key":"9155_CR65","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.adro.2019.03.009","volume":"4","author":"M Gallitto","year":"2019","unstructured":"Gallitto, M. et al. Role of radiation therapy in the management of diffuse intrinsic pontine glioma: a systematic review. Adv. Radiat. Oncol. 4, 520\u2013531 (2019).","journal-title":"Adv. Radiat. Oncol."},{"key":"9155_CR66","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/CCO.0000000000000577","volume":"31","author":"R Aziz-Bose","year":"2019","unstructured":"Aziz-Bose, R. & Monje, M. Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets. Curr. Opin. Oncol. 31, 522\u2013530 (2019).","journal-title":"Curr. Opin. Oncol."},{"key":"9155_CR67","doi-asserted-by":"publisher","unstructured":"van den Bent, M., Saratsis, A. M., Geurts, M. & Franceschi, E. H3 K27M-altered glioma and diffuse intrinsic pontine glioma: semi-systematic review of treatment landscape and future directions. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noad220 (2023).","DOI":"10.1093\/neuonc\/noad220"},{"key":"9155_CR68","doi-asserted-by":"publisher","first-page":"1192448","DOI":"10.3389\/fonc.2023.1192448","volume":"13","author":"K Pandey","year":"2023","unstructured":"Pandey, K. et al. A combined immunopeptidomics, proteomics, and cell surface proteomics approach to identify immunotherapy targets for diffuse intrinsic pontine glioma. Front. Oncol. 13, 1192448 (2023).","journal-title":"Front. Oncol."},{"key":"9155_CR69","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3171\/2009.11.JNS091052","volume":"113","author":"JH Sampson","year":"2010","unstructured":"Sampson, J. H. et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J. Neurosurg. 113, 301\u2013309 (2010).","journal-title":"J. Neurosurg."},{"key":"9155_CR70","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11060-010-0255-0","volume":"101","author":"S Mueller","year":"2011","unstructured":"Mueller, S. et al. Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J. Neurooncol. 101, 267\u2013277 (2011).","journal-title":"J. Neurooncol."},{"key":"9155_CR71","doi-asserted-by":"publisher","first-page":"9342796","DOI":"10.1155\/2019\/9342796","volume":"2019","author":"M Shi","year":"2019","unstructured":"Shi, M. & Sanche, L. Convection-enhanced delivery in malignant gliomas: a review of toxicity and efficacy. J. Oncol. 2019, 9342796 (2019).","journal-title":"J. Oncol."},{"key":"9155_CR72","doi-asserted-by":"publisher","unstructured":"Rechberger, J. S. & Daniels, D. J. Locoregional infusion of IL13R\u03b12-specific immunotoxins in children and adults with high-grade glioma. Ther. Deliv. https:\/\/doi.org\/10.4155\/tde-2022-0019 (2022).","DOI":"10.4155\/tde-2022-0019"},{"key":"9155_CR73","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1158\/0008-5472.CAN-14-3650","volume":"75","author":"RA Bartolom\u00e9","year":"2015","unstructured":"Bartolom\u00e9, R. A. et al. IL13 receptor \u03b12 signaling requires a scaffold protein, FAM120A, to activate the FAK and PI3K pathways in colon cancer metastasis. Cancer Res 75, 2434\u20132444 (2015).","journal-title":"Cancer Res"},{"key":"9155_CR74","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/cncr.22134","volume":"107","author":"M Kioi","year":"2006","unstructured":"Kioi, M., Kawakami, M., Shimamura, T., Husain, S. R. & Puri, R. K. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer 107, 1407\u20131418 (2006).","journal-title":"Cancer"},{"key":"9155_CR75","doi-asserted-by":"publisher","first-page":"8678","DOI":"10.1158\/0008-5472.CAN-09-2100","volume":"69","author":"T Fujisawa","year":"2009","unstructured":"Fujisawa, T., Joshi, B., Nakajima, A. & Puri, R. K. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res. 69, 8678\u20138685 (2009).","journal-title":"Cancer Res."},{"key":"9155_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39018-3","volume":"9","author":"H Okamoto","year":"2019","unstructured":"Okamoto, H. et al. Interleukin-13 receptor \u03b12 is a novel marker and potential therapeutic target for human melanoma. Sci. Rep. 9, 1281 (2019).","journal-title":"Sci. Rep."},{"key":"9155_CR77","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4155\/tde-2022-0055","volume":"14","author":"RN Morgan","year":"2023","unstructured":"Morgan, R. N., Saleh, S. E., Farrag, H. A. & Aboshanab, K. M. New insights on Pseudomonas aeruginosa exotoxin A-based immunotoxins in targeted cancer therapeutic delivery. Ther. Deliv. 14, 31\u201360 (2023).","journal-title":"Ther. Deliv."},{"key":"9155_CR78","doi-asserted-by":"publisher","unstructured":"Dieffenbach, M. & Pastan, I. Mechanisms of resistance to immunotoxins containing pseudomonas exotoxin A in cancer therapy. Biomolecules 10, https:\/\/doi.org\/10.3390\/biom10070979 (2020).","DOI":"10.3390\/biom10070979"},{"key":"9155_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51089-w","volume":"9","author":"S Santajit","year":"2019","unstructured":"Santajit, S. et al. Human single-chain antibodies that neutralize Pseudomonas aeruginosa-exotoxin A-mediated cellular apoptosis. Sci. Rep. 9, 14928 (2019).","journal-title":"Sci. Rep."},{"key":"9155_CR80","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1182>3.0.CO;2-N","volume":"92","author":"SR Husain","year":"2001","unstructured":"Husain, S. R., Joshi, B. H. & Puri, R. K. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int. J. Cancer 92, 168\u2013175 (2001).","journal-title":"Int. J. Cancer"},{"key":"9155_CR81","first-page":"999","volume":"1","author":"M Kawakami","year":"2002","unstructured":"Kawakami, M., Kawakami, K. & Puri, R. K. Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol. Cancer Ther. 1, 999\u20131007 (2002).","journal-title":"Mol. Cancer Ther."},{"key":"9155_CR82","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1023\/A:1026242432647","volume":"65","author":"SR Husain","year":"2003","unstructured":"Husain, S. R. & Puri, R. K. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J. Neurooncol. 65, 37\u201348 (2003).","journal-title":"J. Neurooncol."},{"key":"9155_CR83","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1007\/s00018-016-2130-4","volume":"73","author":"S Matt","year":"2016","unstructured":"Matt, S. & Hofmann, T. G. The DNA damage-induced cell death response: a roadmap to kill cancer cells. Cell Mol. Life Sci. 73, 2829\u20132850 (2016).","journal-title":"Cell Mol. Life Sci."},{"key":"9155_CR84","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fonc.2013.00113","volume":"3","author":"E Mladenov","year":"2013","unstructured":"Mladenov, E., Magin, S., Soni, A. & Iliakis, G. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front. Oncol. 3, 113 (2013).","journal-title":"Front. Oncol."},{"key":"9155_CR85","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ijrobp.2005.05.017","volume":"63","author":"K Kawakami","year":"2005","unstructured":"Kawakami, K., Kawakami, M., Liu, Q. & Puri, R. K. Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines. Int. J. Radiat. Oncol. Biol. Phys. 63, 230\u2013237 (2005).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"9155_CR86","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1088\/0031-9155\/54\/2\/002","volume":"54","author":"R Bromley","year":"2009","unstructured":"Bromley, R., Oliver, L., Davey, R., Harvie, R. & Baldock, C. Predicting the clonogenic survival of A549 cells after modulated X-ray irradiation using the linear quadratic model. Phys. Med. Biol. 54, 187\u2013206 (2009).","journal-title":"Phys. Med. Biol."},{"key":"9155_CR87","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3892\/ijo.2013.1857","volume":"42","author":"NA Franken","year":"2013","unstructured":"Franken, N. A. et al. Cell survival and radiosensitisation: modulation of the linear and quadratic parameters of the LQ model (Review). Int. J. Oncol. 42, 1501\u20131515 (2013).","journal-title":"Int. J. Oncol."},{"key":"9155_CR88","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.bbrc.2017.03.033","volume":"486","author":"T Mamo","year":"2017","unstructured":"Mamo, T. et al. Inhibiting DNA-PK(CS) radiosensitizes human osteosarcoma cells. Biochem. Biophys. Res. Commun. 486, 307\u2013313 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"9155_CR89","doi-asserted-by":"publisher","unstructured":"Masilamani, A. P. et al. An anti-PSMA immunotoxin reduces Mcl-1 and Bcl2A1 and specifically induces in combination with the BAD-Like BH3 mimetic ABT-737 apoptosis in prostate cancer cells. Cancers 12, https:\/\/doi.org\/10.3390\/cancers12061648 (2020).","DOI":"10.3390\/cancers12061648"},{"key":"9155_CR90","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00262-017-2097-5","volume":"67","author":"T Noll","year":"2018","unstructured":"Noll, T., Schultze-Seemann, S., Kuckuck, I., Michalska, M. & Wolf, P. Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737. Cancer Immunol. Immunother. 67, 413\u2013422 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"9155_CR91","doi-asserted-by":"publisher","unstructured":"Tosi, U. & Souweidane, M. Diffuse midline gliomas: challenges and new strategies in a changing clinical landscape. Cancers 16, https:\/\/doi.org\/10.3390\/cancers16010219 (2024).","DOI":"10.3390\/cancers16010219"},{"key":"9155_CR92","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fonc.2019.00092","volume":"9","author":"JP Welby","year":"2019","unstructured":"Welby, J. P. et al. Current murine models and new developments in H3K27M diffuse midline gliomas. Front Oncol. 9, 92 (2019).","journal-title":"Front Oncol."},{"key":"9155_CR93","doi-asserted-by":"publisher","unstructured":"Chen, Z. et al. Advanced pediatric diffuse pontine glioma murine models pave the way towards precision medicine. Cancers 13, https:\/\/doi.org\/10.3390\/cancers13051114 (2021).","DOI":"10.3390\/cancers13051114"},{"key":"9155_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccell.2023.11.002","volume":"42","author":"C Koschmann","year":"2024","unstructured":"Koschmann, C. et al. A road map for the treatment of pediatric diffuse midline glioma. Cancer Cell 42, 1\u20135 (2024).","journal-title":"Cancer Cell"},{"key":"9155_CR95","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fonc.2015.00172","volume":"5","author":"KL Misuraca","year":"2015","unstructured":"Misuraca, K. L., Cordero, F. J. & Becher, O. J. Pre-clinical models of diffuse intrinsic pontine glioma. Front. Oncol. 5, 172 (2015).","journal-title":"Front. Oncol."},{"key":"9155_CR96","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11940-019-0577-y","volume":"21","author":"NA Vitanza","year":"2019","unstructured":"Vitanza, N. A. & Monje, M. Diffuse intrinsic pontine glioma: from diagnosis to next-generation clinical trials. Curr. Treat. Options Neurol. 21, 37 (2019).","journal-title":"Curr. Treat. Options Neurol."},{"key":"9155_CR97","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/neuonc\/noad227","volume":"26","author":"S Mueller","year":"2024","unstructured":"Mueller, S. et al. Consensus framework for conducting phase I\/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group. Neuro Oncol. 26, 407\u2013416 (2024).","journal-title":"Neuro Oncol."},{"key":"9155_CR98","doi-asserted-by":"publisher","unstructured":"Chen, Y., Zhao, C., Li, S., Wang, J. & Zhang, H. Immune Microenvironment and Immunotherapies for Diffuse Intrinsic Pontine Glioma. Cancers 15, https:\/\/doi.org\/10.3390\/cancers15030602 (2023)","DOI":"10.3390\/cancers15030602"},{"key":"9155_CR99","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/neuonc\/noy145","volume":"21","author":"NAP Lieberman","year":"2019","unstructured":"Lieberman, N. A. P. et al. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro Oncol. 21, 83\u201394 (2019).","journal-title":"Neuro Oncol."},{"key":"9155_CR100","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/neuonc\/noac117","volume":"24","author":"ML Persson","year":"2022","unstructured":"Persson, M. L. et al. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies. Neuro Oncol. 24, 1408\u20131422 (2022).","journal-title":"Neuro Oncol."},{"key":"9155_CR101","doi-asserted-by":"publisher","unstructured":"Geng, Z. et al. The open pediatric cancer project. bioRxiv. https:\/\/doi.org\/10.1101\/2024.07.09.599086 (2024).","DOI":"10.1101\/2024.07.09.599086"},{"key":"9155_CR102","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/neuonc\/noac093","volume":"24","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma. Neuro Oncol. 24, 1700\u20131711 (2022).","journal-title":"Neuro Oncol."},{"key":"9155_CR103","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejmp.2021.07.016","volume":"89","author":"L Maigne","year":"2021","unstructured":"Maigne, L. et al. CPOP: An open source C++ cell POPulation modeler for radiation biology applications. Phys. Med. 89, 41\u201350 (2021).","journal-title":"Phys. Med."},{"key":"9155_CR104","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ccell.2017.03.011","volume":"31","author":"S Nagaraja","year":"2017","unstructured":"Nagaraja, S. et al. Transcriptional dependencies in diffuse intrinsic pontine glioma. Cancer Cell 31, 635\u2013652.e636 (2017).","journal-title":"Cancer Cell"},{"key":"9155_CR105","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nm.3855","volume":"21","author":"CS Grasso","year":"2015","unstructured":"Grasso, C. S. et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat. Med. 21, 555\u2013559 (2015).","journal-title":"Nat. Med."},{"key":"9155_CR106","unstructured":"Katzung, B. G. Basic and Clinical Pharmacology. McGraw-Hill Medical (2012)."},{"key":"9155_CR107","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"9155_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform. 12, 323 (2011).","journal-title":"BMC Bioinform."},{"key":"9155_CR109","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fphar.2015.00181","volume":"6","author":"J Tang","year":"2015","unstructured":"Tang, J., Wennerberg, K. & Aittokallio, T. What is synergy? The Saariselk\u00e4 agreement revisited. Front Pharm. 6, 181 (2015).","journal-title":"Front Pharm."},{"key":"9155_CR110","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/978-1-4939-7154-1_30","volume":"1636","author":"J Tang","year":"2017","unstructured":"Tang, J. Informatics approaches for predicting, understanding, and testing cancer drug combinations. Methods Mol. Biol. 1636, 485\u2013506 (2017).","journal-title":"Methods Mol. Biol."},{"key":"9155_CR111","doi-asserted-by":"publisher","unstructured":"Carlson, B. L., Pokorny, J. L., Schroeder, M. A. & Sarkaria, J. N. Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr. Protoc. Pharmacol. Chapter 14, Unit 14.16. https:\/\/doi.org\/10.1002\/0471141755.ph1416s52 (2011)","DOI":"10.1002\/0471141755.ph1416s52"},{"key":"9155_CR112","unstructured":"Paxinos, G. & Watson, C. The Rat Brain In Stereotaxic Coordinates: Hard Cover Edition (Elsevier, 2006)."},{"key":"9155_CR113","doi-asserted-by":"publisher","first-page":"20180744","DOI":"10.1259\/bjr.20180744","volume":"92","author":"SJ van Hoof","year":"2019","unstructured":"van Hoof, S. J., Verde, J. B. & Verhaegen, F. Dose painting by dynamic irradiation delivery on an image-guided small animal radiotherapy platform. Br. J. Radio. 92, 20180744 (2019).","journal-title":"Br. J. Radio."},{"key":"9155_CR114","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1101\/pdb.prot073411","volume":"2014","author":"RD Cardiff","year":"2014","unstructured":"Cardiff, R. D., Miller, C. H. & Munn, R. J. Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harb. Protoc. 2014, 655\u2013658 (2014).","journal-title":"Cold Spring Harb. Protoc."},{"key":"9155_CR115","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","volume":"347","author":"Y Hu","year":"2009","unstructured":"Hu, Y. & Smyth, G. K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 347, 70\u201378 (2009).","journal-title":"J. Immunol. Methods"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-09155-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-09155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-09155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:03:38Z","timestamp":1768903418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-09155-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9155"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-09155-9","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"31 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}